CTRI/2023/07/055473
Recruiting
Phase 4
A Prospective, Multicentric, Single-arm Study to evaluate the effectiveness and safety in Patients undergoing Arthroscopic Bankarts Repair using Knotted UHMWPE Suture Anchor.
Overview
- Phase
- Phase 4
- Intervention
- Not specified
- Conditions
- Health Condition 1: M999- Biomechanical lesion, unspecified
- Sponsor
- Healthium Medtech Limited
- Status
- Recruiting
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\.Male and female subjects between 18 to 40 years of age.
- •2\.Subjects with Bankarts lesion requiring primary Arthroscopic Bankarts repair surgery.
- •3\.Subjects willing to give written informed consent to participate in the study.
Exclusion Criteria
- •1\.Subjects with BMI \=35 kg/m2\.
- •2\.Subjects with history of any surgery to the same shoulder.
- •3\.Subjects with active infection or blood supply limitations.
- •4\.Subjects with pathological conditions of bone or soft tissue that would impair secure fixation.
- •5\.Subjects with known hypersensitivity to UHMWPE
- •6\.Subjects with conditions, which would limit the subjects ability or willingness to restrict activities or follow directions during the healing period.
- •7\.Subjects having any condition that could affect healing (eg. Infections, Regular use of Corticosteroids, Diabetes – HbA1C \= 10\).
- •8\.Subjects with history of heavy smoking (\= 20 cigarettes/day) within the last 6 months.
- •9\.Subjects with a medical or physical condition that, in the opinion of the Investigator, would preclude safe subject participation in the study
- •10\.Subjects who are pregnant or lactating at the time of screening.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Phase 4
A study to assess result after shoulder surgeryHealth Condition 1: M999- Biomechanical lesion, unspecifiedCTRI/2023/04/052027Healthium Medtech Limited
Active, not recruiting
Phase 4
A study to assess result after knee surgeryHealth Condition 1: - Health Condition 2: M999- Biomechanical lesion, unspecifiedCTRI/2023/04/051727Healthium Medtech Limited
Not yet recruiting
Phase 4
The aim is to evaluate the safety and efficacy of MeRes100™ Sirolimus Eluting BioResorbable Vascular Scaffold in coronary artery disease patients.It enhances coronary luminal diameter in symptomatic ischemic heart disease, addressing de novo lesions in native coronary arteries.Health Condition 1: I251- Atherosclerotic heart disease of native coronary arteryCTRI/2024/02/062438Meril Diagnostics Private Limited
Withdrawn
Phase 3
A Prospective, Multi-Center, Single Arm Study of the Conor Cobalt Chromium Reservoir Based Stent (Nevo) with Sirolimus Elution in Native Coronary Artery Lesions (CP-07 protocol)NL-OMON32462Conor Medsystems, LLC (maakt deel uit van Johnson & Johnson); contact persoon Emily Hergenreter40
Completed
Not Applicable
OFT-G1-301 StudyCongenital heart diseaseJPRN-jRCT1080224691TEIJIN LIMITED / TEIJIN PHARMA LIMITED30